{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:04:24Z","timestamp":1790899464474,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":138,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011681","name":"R\u00e4ttsmedicinalverket","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011681","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fsigenetics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Forensic Science International: Genetics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.fsigen.2021.102510","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T20:05:15Z","timestamp":1616789115000},"page":"102510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Oxycodone findings and CYP2D6 function in postmortem cases"],"prefix":"10.1016","volume":"53","author":[{"given":"Gerd","family":"Jakobsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronja","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Pell\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kronstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gr\u00e9en","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fsigen.2021.102510_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1520\/JFS14071J","article-title":"A compilation of fatal and control concentrations of drugs in postmortem femoral blood","volume":"42","author":"Druid","year":"1997","journal-title":"J. Forensic Sci."},{"key":"10.1016\/j.fsigen.2021.102510_bib2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.forsciint.2014.01.005","article-title":"Sedative and hypnotic drugs--fatal and non-fatal reference blood concentrations","volume":"236","author":"J\u00f6nsson","year":"2014","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.fsigen.2021.102510_bib3","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/dta.2655","article-title":"Summary statistics for drug concentrations in post-mortem femoral blood representing all causes of death","volume":"11","author":"Ketola","year":"2019","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.fsigen.2021.102510_bib4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/dta.1507","article-title":"Drug concentrations in post-mortem femoral blood compared with therapeutic concentrations in plasma","volume":"6","author":"Launiainen","year":"2014","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.fsigen.2021.102510_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.forsciint.2016.05.002","article-title":"Antipsychotics \u2212 postmortem fatal and non-fatal reference concentrations","volume":"266","author":"S\u00f6derberg","year":"2016","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.fsigen.2021.102510_bib6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/jat\/28.2.94","article-title":"Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYD2D6 and CYP2C19","volume":"28","author":"Holmgren","year":"2004","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.fsigen.2021.102510_bib7","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jat\/32.8.586","article-title":"Urinary detection times and metabolite\/parent compound ratios after a single dose of buprenorphine","volume":"32","author":"Kronstrand","year":"2008","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.fsigen.2021.102510_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.forsciint.2012.03.016","article-title":"Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome","volume":"220","author":"Selden","year":"2012","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.fsigen.2021.102510_bib9","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/00003088-200443140-00003","article-title":"Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives","volume":"43","author":"Lotsch","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.fsigen.2021.102510_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0379-0738(98)00169-8","article-title":"Cytochrome P450 2D6 (CYP2D6) genotyping on postmortem blood as a supplementary tool for interpretation of forensic toxicological results","volume":"99","author":"Druid","year":"1999","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.fsigen.2021.102510_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.forsciint.2014.03.003","article-title":"Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose","volume":"238","author":"Bastami","year":"2014","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.fsigen.2021.102510_bib12","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/jat\/26.7.438","article-title":"Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases","volume":"26","author":"Jannetto","year":"2002","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.fsigen.2021.102510_bib13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.forsciint.2011.07.034","article-title":"Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood","volume":"214","author":"Kingb\u00e4ck","year":"2012","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.fsigen.2021.102510_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.forsciint.2014.03.018","article-title":"Codeine-related deaths: the role of pharmacogenetics and drug interactions","volume":"239","author":"Lam","year":"2014","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.fsigen.2021.102510_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0379-0738(03)00159-2","article-title":"Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood","volume":"135","author":"Levo","year":"2003","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.fsigen.2021.102510_bib16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.forsciint.2010.09.011","article-title":"Pharmacogenetics in medico-legal context","volume":"203","author":"Sajantila","year":"2010","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.fsigen.2021.102510_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.forsciint.2010.07.011","article-title":"Pharmacogenetics and forensic toxicology","volume":"203","author":"Musshoff","year":"2010","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.fsigen.2021.102510_bib18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/dmd.32.4.447","article-title":"Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes","volume":"32","author":"Lalovic","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.fsigen.2021.102510_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.103.058602","article-title":"Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors","volume":"308","author":"Thompson","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.fsigen.2021.102510_bib20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/009127007701700402","article-title":"Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer","volume":"17","author":"Beaver","year":"1977","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.fsigen.2021.102510_bib21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2125.1991.tb03942.x","article-title":"The pharmacokinetics of oxycodone after intravenous injection in adults","volume":"32","author":"Poyhia","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.fsigen.2021.102510_bib22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2125.1992.tb04090.x","article-title":"The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects","volume":"33","author":"Poyhia","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.fsigen.2021.102510_bib23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","article-title":"Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites","volume":"79","author":"Lalovic","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.fsigen.2021.102510_bib24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2147\/TCRM.S1784","article-title":"Review of oral oxymorphone in the management of pain","volume":"4","author":"Sloan","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.fsigen.2021.102510_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1526-4637.2009.00594.x","article-title":"Clinical pharmacology of oxymorphone","volume":"10","author":"Smith","year":"2009","journal-title":"Pain Med."},{"key":"10.1016\/j.fsigen.2021.102510_bib26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/jat\/bkt077","article-title":"Validation of blood and liver oxymorphone analysis using LC-MS-MS: concentrations in 30 fatal overdoses","volume":"37","author":"Crum","year":"2013","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.fsigen.2021.102510_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jat\/33.3.121","article-title":"Concentration of oxymorphone in postmortem fluids and tissue","volume":"33","author":"Garside","year":"2009","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.fsigen.2021.102510_bib28","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/jat\/33.9.615","article-title":"Case report: oxymorphone-involved fatalities: a report of two cases","volume":"33","author":"McIntyre","year":"2009","journal-title":"J. Anal. Toxicol."},{"key":"#cr-split#-10.1016\/j.fsigen.2021.102510_bib29.1","doi-asserted-by":"crossref","unstructured":"Pharmacogene Variation Consortium (PharmVar) at \u3008www.PharmVar.org\u3009 (Gaedigk et al. 2018, CPT 103:399","DOI":"10.1002\/cpt.910"},{"key":"#cr-split#-10.1016\/j.fsigen.2021.102510_bib29.2","doi-asserted-by":"crossref","unstructured":"Gaedigk et al. 2019, CPT 105:29).","DOI":"10.1002\/cpt.1275"},{"key":"10.1016\/j.fsigen.2021.102510_bib30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tips.2004.02.007","article-title":"Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future","volume":"25","author":"Ingelman-Sundberg","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.fsigen.2021.102510_bib31","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/FPC.0b013e32831ebb30","article-title":"Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales","volume":"19","author":"Sistonen","year":"2009","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.fsigen.2021.102510_bib32","first-page":"284","article-title":"Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences","volume":"60","author":"Sachse","year":"1997","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.fsigen.2021.102510_bib33","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.fsigen.2021.102510_bib34","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/j.forsciint.2012.12.020","article-title":"A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine","volume":"226","author":"Jornil","year":"2013","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.fsigen.2021.102510_bib35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0140-6736(06)69255-6","article-title":"Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother","volume":"368","author":"Koren","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.fsigen.2021.102510_bib36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1399-6576.2009.02104.x","article-title":"Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia","volume":"54","author":"Zwisler","year":"2010","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.fsigen.2021.102510_bib37","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1742-7843.2009.00378.x","article-title":"The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism","volume":"104","author":"Zwisler","year":"2009","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.fsigen.2021.102510_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00228-011-1093-5","article-title":"Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study","volume":"68","author":"Andreassen","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.fsigen.2021.102510_bib39","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/jat\/bkaa051","article-title":"Oxycodone concentrations and metabolic ratios in femoral blood from fatal intoxications and other causes of death using LC-MS-MS","volume":"45","author":"Jakobsson","year":"2020","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.fsigen.2021.102510_bib40","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1007\/s00216-013-6798-0","article-title":"Liquid chromatography\/time-of-flight mass spectrometry analysis of postmortem blood samples for targeted toxicological screening","volume":"405","author":"Roman","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.fsigen.2021.102510_bib41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00228-003-0654-7","article-title":"Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing","volume":"59","author":"Zackrisson","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.fsigen.2021.102510_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060239","article-title":"CYP2D6 genotype dependent oxycodone metabolism in postoperative patients","volume":"8","author":"Stamer","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.fsigen.2021.102510_bib43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2217\/pgs-2016-0183","article-title":"CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients","volume":"18","author":"Balyan","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.fsigen.2021.102510_bib44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00008571-199706000-00004","article-title":"Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution","volume":"7","author":"Marez","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.fsigen.2021.102510_bib45","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0022-3565(25)10669-1","article-title":"Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis","volume":"274","author":"Dahl","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.fsigen.2021.102510_bib46","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00228-004-0800-x","article-title":"Fatal intoxication cases: cytochrome P450 2D6 and 2C19 genotype distributions","volume":"60","author":"Zackrisson","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.fsigen.2021.102510_bib47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/sj.tpj.6500406","article-title":"Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication","volume":"7","author":"Kirchheiner","year":"2007","journal-title":"Pharmacogenom. J."},{"key":"10.1016\/j.fsigen.2021.102510_bib48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/00498254.2019.1648911","article-title":"Cytochrome P450: genotype to phenotype","volume":"50","author":"Waring","year":"2020","journal-title":"Xenobiotica"},{"key":"10.1016\/j.fsigen.2021.102510_bib49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12024-014-9624-x","article-title":"An update on oxycodone: lessons for death investigators in Australia","volume":"11","author":"Pilgrim","year":"2015","journal-title":"Forensic Sci. Med. Pathol."},{"key":"10.1016\/j.fsigen.2021.102510_bib50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.forsciint.2012.07.016","article-title":"Clinical history and characteristics of persons with oxycodone-related deaths in Hillsborough County, Florida in 2009","volume":"223","author":"Ogle","year":"2012","journal-title":"Forensic Sci. Int."}],"container-title":["Forensic Science International: Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187249732100048X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187249732100048X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:05:49Z","timestamp":1761735949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187249732100048X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":51,"alternative-id":["S187249732100048X"],"URL":"https:\/\/doi.org\/10.1016\/j.fsigen.2021.102510","relation":{},"ISSN":["1872-4973"],"issn-type":[{"value":"1872-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxycodone findings and CYP2D6 function in postmortem cases","name":"articletitle","label":"Article Title"},{"value":"Forensic Science International: Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fsigen.2021.102510","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102510"}}